Edesa Biotech, INC Form 4 insider transactions

Pardeep Nijhawan, Chief Executive Officer, a Director and 10% owner of Edesa Biotech, Inc., received 5,324 shares of common stock on August 3, 2026.

Pardeep Nijhawan, CEO and Director of Edesa Biotech, acquired 3,378 restricted share units on July 2, 2026, as part of the company's equity incentive plan.

Edesa Biotech CEO Pardeep Nijhawan acquired 153,550 common shares in a private placement transaction valued at approximately $800,000.

Edesa Biotech CEO Pardeep Nijhawan acquired 1,671 common shares through a restricted share unit grant that vested immediately.

Director Patrick Marshall was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's 2019 Equity Incentive Compensation Plan.

Director Sean Arthur MacDonald was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's 2019 Equity Incentive Compensation Plan.

Director Joan Chypyha was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's 2019 Equity Incentive Compensation Plan.

Edesa Biotech CFO Peter J. Weiler was granted 64,609 restricted share units vesting over a three-year period.

Edesa Biotech President Michael J. Brooks was granted 64,609 restricted share units as part of the company's equity incentive plan.

Director Carlo Sistilli was granted 19,000 restricted share units as part of Edesa Biotech's 2019 Equity Incentive Plan.

Director Charles V. Olson was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's 2019 Equity Incentive Compensation Plan.

Director Da David Liu was granted 19,000 restricted share units in Edesa Biotech, Inc. as part of the company's equity incentive plan.

Edesa Biotech CEO Pardeep Nijhawan acquired 1,159 common shares via a restricted share unit grant.

Edesa Biotech, Inc. reports a transaction involving restricted share units granted to CEO Pardeep Nijhawan.

Edesa Biotech's CEO, Pardeep Nijhawan, acquired 10,000 common shares at $3.90 each, increasing his beneficial ownership.

Edesa Biotech's CEO and 10% owner, Pardeep Nijhawan, acquired 10,000 common shares indirectly at $4.256 per share, effective March 4, 2026.

Edesa Biotech's CEO, Pardeep Nijhawan, acquired 10,000 common shares, signaling increased confidence in the company.

Edesa Biotech's CEO and 10% owner, Pardeep Nijhawan, increased his beneficial ownership through direct purchases and a restricted share unit grant in late February and early March 2026.

Edesa Biotech's CEO, Pardeep Nijhawan, received a grant of 82,236 restricted share units as part of his 2025 cash bonus.

Edesa Biotech's CEO, Pardeep Nijhawan, increased his beneficial ownership by 11,168 common shares through a restricted share unit grant.

Edesa Biotech's CEO, Pardeep Nijhawan, reported the acquisition of 10,444 common shares through a restricted share unit grant.

Edesa Biotech's CEO, Pardeep Nijhawan, reported the acquisition of 8,766 common shares through a restricted share unit grant.

Edesa Biotech's CEO and 10% owner, Pardeep Nijhawan, acquired 6,968 common shares through a restricted share unit grant that vested immediately.

Edesa Biotech's CEO, Pardeep Nijhawan, acquired 5,908 common shares through a restricted share unit grant, increasing his total beneficial ownership.

Edesa Biotech's CEO and 10% owner, Pardeep Nijhawan, received a grant of 5,981 restricted share units that vested immediately.

Edesa Biotech's CEO, Pardeep Nijhawan, received a grant of 6,802 common shares as restricted share units, vesting immediately.

Edesa Biotech's Chief Executive Officer, Pardeep Nijhawan, reported the acquisition of 7,186 fully vested common shares through a restricted share unit grant, increasing his total beneficial ownership to 916,381 shares.

Edesa Biotech, Inc. Director Patrick Marshall was granted 11,000 restricted share units, vesting over 12 months, as reported in a recent SEC Form 4 filing.

Edesa Biotech, Inc. Director Charles V. Olson was granted 11,000 restricted common shares as part of the company's 2019 Equity Incentive Compensation Plan, signaling continued alignment with shareholder interests.

Edesa Biotech, Inc. Director Carlo Sistilli was granted 20,001 restricted share units, vesting over twelve months, as disclosed in a recent SEC Form 4 filing.